Compare Mesoblast Limited (MESO) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Invesco S&P 500 Low Volatility ETF — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Invesco S&P 500 Low Volatility ETF trades at $75.71. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SPLV | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $77.45 |
52-Week Low | $12.88 | $70.30 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SPLV trades at $76.09, down 0.63% today, with a bullish technical outlook supported by moving averages and key support at $76. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty, with recent news highlighting its defensive appeal during tech sell-offs and geopolitical tensions. Dividend distributions are scheduled for mid-2026 at $0.14 per share.
Outlook remains positive for risk-averse investors seeking equity exposure with reduced volatility, though reliance on market sentiment and interest rate trends poses risks. The ETF's strategy aligns with current defensive positioning, but limited growth potential may cap upside compared to broader market indices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
